JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD.

Financials Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Equities

688076

CNE1000051X5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
60.22 ^CNY	+0.30%		+7.48%	+33.97%

Apr. 22	Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,811	4,890	9,583	12,838	-	-
Enterprise Value (EV) ¹	8,811	4,890	9,583	12,838	12,838	12,838
P/E ratio	68.9 x	37.6 x	59.1 x	55.4 x	38.9 x	28.1 x
Yield	-	-	0.89%	0.51%	0.79%	1.08%
Capitalization / Revenue	13.7 x	7.51 x	9.25 x	8.73 x	6.36 x	4.69 x
EV / Revenue	13.7 x	7.51 x	9.25 x	8.73 x	6.36 x	4.69 x
EV / EBITDA	41.1 x	21.4 x	29.4 x	29.5 x	21.9 x	16.5 x
EV / FCF	-	-	-	-26.9 x	-35.5 x	39 x
FCF Yield	-	-	-	-3.72%	-2.82%	2.56%
Price to Book	4.86 x	2.56 x	4.37 x	5.55 x	4.97 x	4.36 x
Nbr of stocks (in thousands)	213,184	213,184	213,184	213,184	-	-
Reference price ²	41.33	22.94	44.95	60.22	60.22	60.22
Announcement Date	2/27/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	643.9	651.3	1,036	1,470	2,018	2,735
EBITDA ¹	-	214.2	228.3	326	434.7	587	780
EBIT ¹	-	128.3	124.9	189.1	268.8	384.8	538
Operating Margin	-	19.93%	19.17%	18.26%	18.28%	19.06%	19.67%
Earnings before Tax (EBT) ¹	-	125.7	123.2	170	257	362.7	510.3
Net income ¹	123.4	115.4	129.1	161.3	231.5	329.2	456.2
Net margin	-	17.92%	19.82%	15.58%	15.75%	16.31%	16.68%
EPS ²	0.7700	0.6000	0.6100	0.7600	1.088	1.550	2.142
Free Cash Flow ¹	-	-	-	-	-478	-362	329
FCF margin	-	-	-	-	-32.52%	-17.93%	12.03%
FCF Conversion (EBITDA)	-	-	-	-	-	-	42.18%
FCF Conversion (Net income)	-	-	-	-	-	-	72.11%
Dividend per Share ²	-	-	-	0.4000	0.3050	0.4750	0.6500
Announcement Date	4/25/21	2/27/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q2	2023 Q3
Net sales	-	-
EBITDA	-	-
EBIT	-	-
Operating Margin	-	-
Earnings before Tax (EBT)	-	-
Net income ¹	20.84	49.86
Net margin	-	-
EPS	0.1000	-
Dividend per Share	-	-
Announcement Date	8/28/23	10/20/23

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	-478	-362	329
ROE (net income / shareholders' equity)	-	7.97%	6.94%	8.18%	10%	12.8%	15.5%
ROA (Net income/ Total Assets)	-	-	-	5.29%	6.12%	7.66%	9.37%
Assets ¹	-	-	-	3,050	3,786	4,298	4,869
Book Value Per Share ²	-	8.500	8.960	10.30	10.90	12.10	13.80
Cash Flow per Share ²	-	0.8500	0.1400	1.640	1.540	1.000	1.130
Capex ¹	-	233	438	659	391	377	227
Capex / Sales	-	36.19%	67.3%	63.64%	26.58%	18.68%	8.29%
Announcement Date	4/25/21	2/27/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

60.22 CNY

Average target price

62.24 CNY

Spread / Average Target

+3.36%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD.	+33.97%	1.77B
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.50%	358B
MERCK & CO., INC.	+19.35%	328B
ABBVIE INC.	+3.59%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.67%	165B

Other Pharmaceuticals